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The criticaJ role that androgens play in the etiology of acne 
has led to a search for topically active antiandrogens and the 
frequent use of the flank organ of the golden Syrian hamster 
as an animal model. 17-a-propyltestosterone (17-PT) has 
been identified as ha ving potent 3ntiandrogen.ic activity in 
the hamster model , and this report describes its clinical evalu-
ation. Two double-blind placebo controlled studies compar-
ing 4% 17 -PT in 80% alcohol versus vehicle alone were 
conducted. One study examined 17-PT sebosuppressive ac-
t ivity in 20 subjects. The second study examined its effi cacy 
in 44 subjects having mild to moderate acne. A third study 
For many years now the critical role of androgens in the etiology of acne has been recognized 11] and th is has led to a search for phannacologic agents that selectively block the: action of androgens on the sebaceous gland. Inasmuch as the systemic use of antiandrogens is likely to 
be accompanied by significant adverse reacrions second.u-y to effects 
on other androgen sensitive structures. the search fo r efficacious 
topical agents has become the more ranonal approach. 
Following a systematic scre~ ning of androstane and androstene 
analogues of testosterone, Ferrari et al [2J reported on the discovery 
of a compound, 17-a -propyl testosterone (17-PT). which effec-
tively suppressed androgen-induced enlargement of the sebaceous 
gland in two animal models. the flank organ of the Syrian hamster 
and the supracaudal gland of the guinea pig. T opical appliation of 
thi s compound to mature male hamsters induced a reve rsible regres-
sion of the fl ank organ in ;a dose-de~l1de.nt f;ashion with no evi-
dence of systemic acti vity. The effect was seen with doses ranging 
from 10-250 /lg/ day, incorporated in S /ll ethanol and directly ap-
plied to the skin overl ying the fl ank organ. The mechanism of 
action of this drug is thought to be direct blockade of dihydrotestos-
terone binding to tissue receptors [3]. 
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Abbreviations: 
N/ C: nodules/ cysts 
Pap: papule 
Pust: pustule 
Ro 15-0778: {E)-l ,2,3,4,-tetrahydro- I,1 ,4.4,-tea:unethyl-6-
(1 -methyl-2-phenylethenyl)naphthalene 
SER: sebum excretion rate 
17-PT: 17-a-propyhestosterone 
measured in vitro percutaneous absorption of 17 -PT through 
hamster flank and monkey skin, and human face skin in-vivo, 
using radioactive drug. 17-PT was found to be ineffective in 
reducing either the sebum excretion rate or the number of 
inflammatory acne lesions. Failure of 17-PT to show clinical 
activi ry was not a result of poor percutaneous absorption. 
Total absorption in man was 7.7% of the dose and only 1.0% 
in the hamster. The sebaceous gland ofhamSler flank organ is 
apparendy more sensitive to antiandrogens than the human 
sebaceous gland.) Illvest DermatoI93:475 - 479, 1989 
Although 17-PT was later clinically evaluated in the treatment of 
acne , it was found to be with om efficacy in man, and the resuJrs 
were never published. Recently, preliminary publication [4,5] of 
da ta on a second drug (Ro 15-0778), which was found to suppress 
the sebaceous gland in animal models but was without effect in man, 
has been noted. This has prompted us {Q repo" the data originally 
obtained on 17-PT and to question the continued we of the hamster 
fl ank organ model for the study of the human sebaceow gland. 
The data presented here arc derived from three separate studies. 
The percutaneous abso rption of 17-PT has been evaluated in a series 
of in vitro and in vivo studies. and clinical evaluations ofboch sebum 
suppression and efficacy in acne have been conducted in human 
volun teers. 
MATERIALS AND METHODS 
17-PT (17-a-propylandrost-4·en-I7p-ol-3-one, W IN 17,665) was 
supplied by Sterl ing-W inthrop Research lnstitute (Rensselaer, NY) 
(Fig I). 
The formulation used in all studies involving topical appl ication 
of the drug was 4% (w/ v) 17-PT in a vehicle consisting of 80/ 20 
e-th:molfwater. For the acne and sebum suppression studies the for-
mulatinn was suppl ied as saturated fiber pads, packaged 42 per jar. 
For the percutaneous absorption an.d bioavailability studies, carbon-
141abcJed 17-PT, specific activity of3.7 /lei/ mmole. was incorpo-
rated into the standard stock formulation in tr2cer amounts. The 
one exception involved subcutaneow injection in the monkey, 
where only radioactive drug was used ( 0 take advantage: of a higher 
specific activiry. In this case a 1.2% solution of drug in 95% ethanol 
was used. 
Approval to conduct the: in vivo studies was obt2l.ned from the 
appropriate Human Subjects Investigational Review Boards. Writ-
ten infonned consent was obtained from 211 subjects including pa-
rent2l consent where necessary. 
Percutaneous Absorption Studies In vitro percutaneous 2b-
sorption studies were conducted using a previously publ ished tech-
nique [61. Essentially. tbe method consists of mounting full-thick-
ness skin on specia.ll y constructed diffusion chambers (Crown Glass 
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Figure 1. Chemical structUre or 17..a-propyltesrosterone. 
Co .• SomerviJIe, NJ). The dennis is bathed by isotonic saline 
(pH 7.4). maintained at 37 ·C. and stirred magnetically. The epi-
dennis is open to the ambienr laboratory environment. Serial 
chamber samples were collected and analyzed speCtroradiomeui-
cally. 
HtlttlSU!r: Six mature male Syrian hamsters (Charles River labora-
tories) were killed by Nembutal injection and the hair on the back 
c10sd y shaved with electric clippers. Duplicate full -thickness speci-
mens from both flank organ-conuining skin and non-flank organ 
skin were (:I .. ken from each animal and mounted on diffusion cells in 
which 1.0 crn2 of skin surface was available for study. Following a 
I-h equilibration period, 10 p:l of radioactive test solution was ap-
pl ied to the epidermal surface. and absorption was assessed by re-
moving the dermal bathing solution in toto at regular intervals and 
analyz ing for radioactive content. 
Mot/key: Back skin from three monkeys (Macaca nemcsrrina) was 
obtained through the Unive.rsity of W as hington Regional Primate 
Center Tissue Program. Skin was prepared. mounted onto diffusion 
chambers, and percutaneous absorprion of 17-PT was performed as 
described above. 
Subcutaneous injection of 17-PT was also perfonned in the 
rhesus monkey in order to determine fractional urinary excretion, a 
factor needed for the calculation of total absorption following top,i-
cal appl ication in man (see below). Three adult rhesus monkeys 
(Macaea mulatta) were tranquilized wi th Ketamine; a portion of 
their backs was shaved with cleerric cl ippers; and the animals were 
placed in metabolism chairs (Plas-Labs. Lansing, MI). iUdioacnve 
t 7-PT, approximately 10,uCi in 0.075 ml ethanol, was injected 
into the subcuuneow space of [he back wing a microsyringe. Tota.! 
urinary ourput was collected for 5 d and analyzed for radioactive 
content to determine the fractional dose excreted in the urine. 
Huma'l: Human abdominal skin was obtained ar autopsy from 
three adul t donors, moumed on diffusion chambers, and percutane-
ous absorption of 17-PT was performed as previously described. 
Th.e in vivo percutaneous absorption of 17-PT was evaluated in 
five healthy young adult male subjects. The subjects were prohib-
ited from using topical medications for I week prior to the start of 
the study. None of the subjects had used topical or systemic reri-
noids .. 
On the morning of the first study day . 15 min pdor to dosin%, 
control urine specimens were collected from each subject and a mild 
soap (Alpha-Ken.) and water wash of the face completed. T hen 
0.1 mJ of radioactive test solution was applied by micropipette to 
50 cm2 face skin, equally divided berween cheek and forehead, and 
evenly spread with a gtass rod. .. The subjects were allowed to go 
about their normal daily activities but were instructed not to rub or 
wash their faces and to avoid activities that would stimulate sweat-
ing. Radioactive drug remained on the face for 10 h, then was 
washed off with soap and water. 
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Tora! urinary output was collected for 5 d at 2.S-h intervals for 
the first 10 h and at approximately 12·h intervals thereafter. Five 
milliliters of each urine specimen was gelled with 10 ml scintilla-
tion fluid (Aquasol-lI) a.nd counted in a liquid scintillation spec-
trome.ter. Que.nching was corrected by the external standard 
method. Parricularly dark urine specimens were fint diluted with 
diS[iJled water prior to sampljng. 
Ten-milliliter blood samples were obtained at the same time 
points as urine collections were made and serum was separ,tted. 
Duplicate O.5-ml aliquots of serum were taken and each added to 
4.5 ml water, gelled with 10 011 scintillation fluid, and coumed. 
Tot'al percuraneous absorprion of 17-PT was calculated from the 
summarion of all radioactivity found in the urine and the use of a 
correction factor to adjust for radioactivity excreted vi.a other routes. 
The correction fdetor, i.e .. the fraction of a systemically adminis-
tered dos~ co be excreted in the urine. was determined in the experi-
menu in which radioactive 17-PT was injected subcutaneously in 
the monkey as described previously. 
Acne Efficacy and Sebum Suppression Studies The efficacy 
of 17-PT in the treatment of acne was assessed in a placebo-con-
trolled. double-blind study. Forty-four male subjects, ages 14 - 20, 
having mild [ 0 moderate facial acne and a minimum lesion count of 
10 papules/pustules. were recruited and randomly assigned to ei ther 
active or placebo treatment. For each subject a history was taken and 
physica l examination and screening laboratory evaluations were 
done prior CO [he start of rhe study. No form of acne therapy other 
than the te"st medication was allowed during the study. and subjects 
had to be off all systemic antibiotics for 1 month and all topical 
medications for 2 weeks prior to initiation of tht' test therapy. 
Th e- study ran for 12 weeks with rhe test medication being ap-
plied three times dail y. Subjects werC instructed ro make the morn-
ing and evening applications following a face wash. Efficacy was 
evaluated by lesion count, and the subjects were seen at O. 2, 4, 6. 8, 
and 12 weeks. At each visit all inflammatory lesions on the en tire 
face were counted and recorded. In addition. the oiliness of four sites 
(chin, cheeks. nose, and forehead) were graded individually by in-
spection using a 0-3 scale. where 0 represented no oil and 3 repre-
sented extreme oiliness. For purposes of statisncal analysis the 
grades for the four sites were summed. Signs of irritation were also 
nored. At the end of the study the code was broken and S[atistical 
evaluation of the r~ults made. 
The ability of 17 -PT to reduce the rate of sebum excretion was 
evaluated in a separate double-blind, placebo-controlled srudy in 20 
health y males, 22-3 1 yea rs of age, having mild to moderate acne. 
Each was given a physical examin ..:aion, including screening labora-
tory evaluation to insure that rhey were in good health, then ran-
domly assigned to eicher active or placebo treatment. All topical 
therapy must have been discontinued at least 1 wt"ek prior to entry 
into the study. 
The study was divided into two phases: a 3-week control period 
during which onl y placebo pads were used by all subjects. and a 
9-week treatment period during which those assigned to active 
therapy received drug-conta ining pads. Application was three times 
daily for all subjects during both phases. During the 3-week control 
period. weekl y evaluation of the sebum excretion rate (SER) of 
forehead skin and plasma testos terone was made for the purpose of 
Table l. Percutaneous Absorption of 17-PT-
Total Absorption 
Animal Site Method % Dose # E'Xpts 
Hamster Gland in vitro 1.0 ± 0.3 6 
Hamster Non-gland in vitro 2.3 ± 1.3 6 
Monkey B:l.ck in vitro 1.4 ±O.9 3 
M,n Abdomen in vitro 0.4 ± 0 .. 2 3 
Mon Face in vivo 7.7 ± 3.3 5 
• TOI:!I ~luorpuon is the mt:~n and sund.nd deyution meuurt·d:as the pc-fCC'nl ohhe 
~pphcd dOK. 
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Figure 2. Urinary excretion of 14C·17_PT from ii's topical application to thr faCt' offive hunun volunteers. The lint is tbe besr fit of the individuaJ sample 
points. W: surface wa.!ih timc. 
establishing baseline values. During the treatment phase these pa-
rameters were measured ar 4, 6. 8, and 9 weeks. 
The SER was determined gravimetrically following a 3-h collec-
tion period using a previously published technique (71, and plasma 
testosrctO,nc was determined by radioimmunoassay. 
RESULTS 
Data obtained on the percutaneous absorption of 17-PT in the ham-
ster, monkey. and man are p resented in Table I. 17-PT absorption is 
generally found to be low, except for human face skin. irrespective 
of the species examined. Skin overlying the flank organ of the 
hamster is no more permeable than that of adjacem non-gland skin 
or that of monkey skin. In fac t , skin overlying the Aank organ is 
statistically less permeable: (p=O.OS) chan that of adjacent skin 
(1.0% versus 2.3% of the applied dose). 17-PT absorption through 
human abdominal skin (0.4%) is even lower than either hamster 
(1-2.3%) or monkey skin (1.4%). However, 17-PT absorption 
through (ace skin is conside rably higher (7.7% of the app lied dose). 
T he rate of urinary excretion of radioactivity following applica-
tion to the (ace of five volunteers is shown ill Fig 2. The rate of 
excretion rises steadily until the rime of rhe face wash at 10 h, then 
falls. Serum levels of radioactivity (nor shown) follow in :Ii similar 
fashion. The highest serum level of 17- PT is seen at 10 h and is 
eguivalenr to approximately 10 ng/ rol of parenr drug (range = 2-
22 ng/ ml). The amount of radioactivity detected in the serum was 
tOO Jow to ancmpt to identify the nature of the chemical species 
carrying the label. 
A summary of the results obtained in the acne clinical study is 
givcn in Table n. As there were no clinically significam differences 
secn berween the placebo and active formuladons at any of the 
intermediate grading periods, only the data from the baseline and 
final grading periods arc presented. 
It can be seell that, with one exception, there are no differences 
berween active and placebo treatment at week 12 in the parameters 
papules , pustules, or oi liness. With respect to papules and pustules, 
not even a placebo effect is noted in this study, i.e., there is no 
improvement from week 0 ro J 2. A non-significant trend toward 
improvement in the oiliness score with time is seen for both active 
and placebo trcatmem. This effect is probably attributable to the 
physicaJ removal of surface oil secondary to t.i.d . use of the ethmol 
saturated pads. 
The single paramNer in which a sta[istically significant differ-
ence berween active and placebo trearment is seen ar week 12 is wirh 
nodules/ cysts (N / C). In view of the facr that the study was not 
Table D. Effect of 17-PT on the T reatment of Acnea 
Wcek 0 Week 12 
Trr:ument Paph Pust" N/C' Oil Papb Pust" N/ C' Oil 
Me2n 15.9 5.2 1.0 11 .8 19. 1 4.7 1.7 6.3 
Placebo 
SD 10.0 3.9 1.9 3.2 8.6 5.5 2.5 6 .0 
Me2n 20.5 5.6 0.8 9.9 19.3 4.1 0.4 7.1 
Active 
SD 9.9 4.6 1.8 3.3 12.0 4.6 0.6 5.0 
• Mean .nd standard d~vi.uion or lesion counu and oiliness score. 
~ Plp: papules. 
~ Pusr: pu.nulr:s. 
d N/ C: nodults/cym. 
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T able m. Effect of 17-PT on Sebum Excretion Rate" 
Conrrol Period (week) 
Trcatm('m 2 3 
Placebo M Crln 2. 19 1.95 2.09 
SO 0.68 0.55 0.66 
Activt' Mean 2.41 2.44 2.42 
SO 0.79 0.83 0.77 
• Mean ~lId s[J.Ild:ira 0,:\· .a1l0n of scbum cxcrcoon cxprt'lSCd ;as mg/ l0 em'/3 h 
designed to primarily examine nodulo-cystic acne and tbe- number 
of lesions in the N/C category are very small, the difference be-
tween treatments is felr to be a chance occurrence onJy. In keeping 
with rhis conclusion it should be noted that rhe difference bern'een 
week 0 and week 12 in the N/C count is nor statistical ly signincant 
for eirher active or placebo therapy. 
The effect of 17~PT on the SER is shown in Table III. Nineteen 
of che twemy test subjects successfully completed the entire course 
of therap}'. One subject was dropped after failing to return for three 
of the four eval uation visits. N o statistically signi6cam differe.nces 
were observed at any time point between active and placebo ther-
apy , nor were any significant differences observed between the con-
trol {mean} and treatment period [or I:ither active or placebo ther-
apy. Two subjects in rhe- placebo group experienced some transie.nt 
facial irritarion during th" course of the stud y. H owever, both were 
able to continue in the stud y, and the reactions disappeared without 
the need for rreatme.nt. 
The effect of 17- PT on plasma testosterone levels of the same 
ninctcen subjects is presented in Table IV. There were no statisti-
cally significant differences becween aCtive and placebo therapy at 
an y time point nor were there any signilicam differences between 
the control (mean) and treatment period for either active or placebo 
therapy. 
DISCUSSION 
The ~ank organs (costoverrebr.al glands) of the golden Syrian ham-
ster are widely used as a model for the human sebaceous gland (8). 
They are gross ly vlsible paired structureS, situated on the back of r.h e 
animal , and comain sebaceous g lands, large pigmented hair folli-
cles, and dermal me1anocytes. The utility of the flank organ to the 
dennatopharmacologist derives from rhe fact that all three of its 
components are androgen sensirive, alrhough most work fO date has 
focused on the sebaceous glands. In the mature male hamster tbe 
sebaceous glands are palpable , 6 - 8 mm in diameter, and almost fill 
the entirety of the dermis. In immature males, castrated m:tles, and 
mature femal es, the g lands are much smaller but can be stimulated 
to full porential by topical or parenteral administration of testoster-
one or other androgens . 
This response to androgen adm.inistration has become the basis of 
the model and has allowed invc:stigators {O sysrematically screen 
drugs fo r their ability to block the stimulatory effect of androgens, 
i.e .. to screen for antiandrogeru. The model can be further refined 
with respect ro tOpically applied anriandrogens in that local -versus-
systemic activity can be deduced. Unilateral administration of a 
systemically active drug will lead to an effect on both. glands, 
Trcatmenr Period (week) 
Mean 4 6 8 9 
2.08 2.36 2.15 2.22 2.22 
0.61 0.81 0.76 0.56 0 .62 
2.42 2.16 2.22 2.35 2.34 
0.78 0.74 0.75 0.87 0.79 
wbereas a locally active drug will fail to affect the contralateral 
gland. 
Recent work suggests that the use of the hamster flank organ as a 
screening model to identify the rapcu tkally effective drugs may be 
seriously flawed. Vane et al [5] have shown that a retinoid deriva-
tive , Ro 15-0778, highly acrive in the hamster flank organ as well as 
in castrated testosterone stimulated rats, is without effect in man. 
More imporralldy, they have demonstrated that its clinical failute is 
not a result of poor bioavailability in man. Following 12 weeks of 
rreatlnent in, 10 acne subjects at an oral dose of 11 mg/ kg/ day , the 
sebum level of parem drug was found [0 be 61 ± 49 ng/ mg. Al-
though this sebum drug level did not result in a reduced SER, it was 
equal to the sebum drug level measured in the rat (52 ng/mg) , 
wbich was associated with a 70% - 86% reduction in the rat 's SER. 
Moreover. the sebum drug level seen in man was greater than the 
30.5 ng/ mg level measured in the hamster flank organ following 
oral dosing. a level which was associated wirh a 43% reduction in 
gland weight. Thus. scbum or tissue levels that are sufficient to 
produce a pharmacologic effect in the hamster and rat were wirhout 
effecr in man. 
Review of the literatUre disclosed additional examples of model 
failure. Spironolactone [9.10J. cyproterom; acetate it 1,12,13,14], 
and flmamide ('15 .161 '111 exhibited ami:mdrogcnic :lctlviry in the 
flank organ when applied topically, yet have not shown clinically 
significant topical efficacy in man. The latrer two drugs. however, 
appear to exert [heir inhibitory effects on the flank organ via a 
s}'stemic rather than local route, i.e., bilateral reduction in gland size 
was noted following unilateral application [9,11.15] . T hus. [heir 
clinical failure following copical application may simply reflect the 
much larger vol ume of distribution in man. 
The data obtained in the present study offer further proof that the 
hamster flank organ model fails to accurately predict therapeutic 
efficacy in man. Though active topically in the hamster at doses 
ranging from 10 - 250 Jig/day (equivalent to s.olutions ranging 
from 0.2 - 5.0% in concentration), in man a 4.0% solution of 17-PT 
was found to be ineffective in the treatment of acne as well 3..,; in the 
inhibition of SER. Given the known differences in percutaneous 
absorption between the skin of animals and man, ir seemed likely 
that rhe therapeutic failure observed in the present study might well 
be due to low drug permeation in man. H owever, because direct 
measurement found human face skin to be more penncable than the 
skin overlying the flank organ (7.7% versus 1..0% of tbe dose, re-
spectively), it is clear that differences in absorption cannot account 
for the observed differences in pharmacologic activity. ThC' possibil -
iry of d ifferent skin metabolic profiles of 17-PT in hamster and man 
Table IV. Effect of 17-PT on Plasma Testosteronea 
Control Period (week) Treatmenr Period (week) 
Treat'menr 2 3 Mean 4 6 8 9 
Placebo Mean 0 .66 0.64 0.59 0 .63 0.58 0.71 0 .72 0.69 
SO 0.21 0. 18 0.15 0.16 0.11 0.16 0.14 0.18 
Active Mean 0 .74 0.68 0.72 0.71 0.6 1 0.75 0.75 0.73 
SO 0.19 0 .16 0.16 0.12 0.10 0.10 0.14 0.09 
• Mean :Iond st.ndard deViation exprened U Jlg/ ntl serum. 
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as an exp!an~tion of the observed species differences cannot be rul ed 
o ut at chIs nme, 
Altho ugh the sin gle failure of the hamster flank organ modc::l 
reported here does nor j ustify condemnation of the modc::l , wh en 
coupled with the recentl y reponed experience on Ro 15-0778 one 
must serio usly question the relevance of the model. 17-PT is an 
antiandrogen whose activity is dependent u pon blockade of the 
dihyd roteslosterone recepror. Ro 15-778 is a retino id whose mecha-
nism of action is unclear, but which is known to be devoid of 
antiandrogen activity and, the re fore, is acting by a m echanism unre-
lated to that of 17-PT. Given that twO d rugs of unrelated structure 
and pharmacologic aCfiviry both fail in man, in spite of unequi vo-
cally good activity in the flank organ and comparable topical bio-
availabili ty, it is clear that the model has failed. 
What is particula rly puzzling is the failure of the £lank o rgan 
m odel to accurately predict the lack of efficacy of Ro 15-0778, 
because prior work with re tinoids had shown good correlation be-
tween the model and clinical efficacy. In a study directly comparing 
isorretinoin with the aromatic retinoid er retinate , both dosed by 
subcutaneous injection, Gomez [17] found that isorretinoin signifi -
cantly suppressed tbe flank o rgan, whereas e trerinatc w as virtuall y 
without e!lect. These results parallel th e clinical observations of 
Goldstein et al [18J. in which erret illate was found to be much less 
efficacious than isorretinoin in the treatment of nodulo-cystic acne. 
The reduction in SER and lesion count at [he end of therapy (8 
weeks) was 2 1% and 8% fo r etretinate, versus 86% and 43% for 
isotretinoin. 
One explanation for rbe disparate results obtained with the aro-
ronoid derivative Ro 15-0778 m ay be that this dru g is not a typical 
retino id or. perhaps . not a rerinoid at all. In most bioassay systems 
used to screen rerinoids. this drug is inactive. Connor et al[19 1 have 
shown chat it fails to ind uce epidermal hyperpl asia in rhe hairless 
mouse following ropical application . Loeliger et al {20J have shown 
that it fails to induce regression of established skin papillomas in 
mice following intt2periro neal injection. With rhe exception of tbe 
h amster flank organ. th(': only test system in which Ro 15-0778 
shows activity is in reversal of keratinization in rhe retinoid-defi-
cient hamster trachea model [211. Thus. the cl inical faiJure of Ro 
15-0778 may have little relevance to the use of the flank organ as an 
efficacy screen for ret inoids. 
We do not suggest the abandonment of rhe Hank organ model. 
but rather a better understanding of its biochemical makeup and 
pharmacologic response relative to the human sebaceous gland. 
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